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Objectives. This study was conducted to assess the efficacy of
sulodexide, a glycosaminGglycan compound with antithrombotic
properties, in preventing death and tlsronsisoersahoisc events after
acute myocardial infarction .
Background. Antithrombotic therapy has been found to play
an important role in the prevention of cardiovascular events and
death after acute myocardial infarction . Glycosaminoglycan-
containing compounds, including sulodexide, show profibrimplytic
and antithrombotic properties that render them suitable for use in
patients after infarction .
Methods. A total of 3,96 patients who had recovered from
acute myocardial infarction were randomized to receive either
the standard therapy routinely administered at each study
center, excluding antiplatelet and anticoagulant drugs (control
group, 1,970 patients), or the standard therapy plus sulodexide
(treated group, 2,016 patients) . Between 7 and 10 days after the
episode of acute myocardial infarction, sulodexide was ad-
miMsWivd as a single daily 600-lipoprotein-lipase--releasing
unit (LRU) intramuscular injection for the 1st month, followed
It is now generally accepted that plaque rupture leading to
thrombus formation and coronary occlusion is the most
frequent pathophysiologic basis for acute coronary syn-
dromes (1-3) . Because survivors of acute myocardial infarc-
tion are at risk of recurrent infarction and cardiac death
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by oral capsules of 500 LRU twice daily . Patients were evaluated
for >12 months,
Results . At the end of the study, 140 deaths (7,1%) were
recorded in the control group and 97 (4 .8%) in the sulodexide
group (32% risk reduction, p = 0.0022, chi-square test) . A total of
90 patients (4.6%) in the control group had a further infarction,
compared with 66 (3 .3%) in the sulodexide group (28% risk
reduction, p = 0.035) . Furthermore, a reduction in left ventric-
ular thrombus formation (evaluated by echocardiography) was
observed in the sulodexide group (n = 12; 0 .6%), compared with
values in the condol group (n = 25 ; 1.3%) (53% risk reduction,
p = 0 .027) . Sulodexide was well tolerated and devoid of significant
adverse events . All significant results were confirmed by "actual
treatment" analyses .
Conclusions . The study provides evidence that long-term ther-
apy with sulodexide started early after an episode of acute
myocardial
infarction is associated with reductions in total mor-
tality, rate of reinfarction and mural thrombus formation .
(J Am Coll Cardiol 1994,23 .27-34)
(4-6), several clinical trials (7-10) have been conducted
using different antithrombotic drugs alone or in combination
for secondary prevention of coronary heart disease. It has
been shown (9) that platelet inhibitors are able to reduce the
cardiovascular mortality ~ -
ate by 13%, nonfatal reinfarction
by 31% and all important vascular events by 25%
. Similar
results have been obtained with subcutaneous injections of
low dose heparin (W) and warfarin (8)
.
Sulodexide is a highly purified preparation containing an
endogenous-like, fast-moving heparin fraction (iduronyl-
glycosaminoglycan sulfate) with a high affinity for antithrom-
bin (80%) and a dermatan fraction with an affinity for heparin
cofactor (20%) (11) . In vivo antiatherosclerotic activity has
been demonstrated by sulodcxide (12,13) and may be related
to a hypolipidemic activity linked to lipoprotein-lipase re-
lease (12,14), a more rapid catabolism of cholesterol-rich
lipoproteins (very low density lipoproteins-low density lipo-
0735-1097194/$6.00
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proteins (VLDL-LDL]) by the liver (15) and an antiprolifer-
ative effect on smooth muscle cell types (16). In various
animal models, sulodexide also shows antithromhotic activ-
ity, probably by blocking platelet activation by thrombin, by
an inhibitory effect on platelet adhesion (17) and through its
anticoagulant and profibrinolytic activity (18) .
At therapeutic doses in patients, sulodexide inhibits acti-
vated factor X without influencing the activated partial
thromboplastin time and thrombin time (19,20) . It also exerts
a profibrinolytic activity, evidenced by tissue-plasminogen
activator (t-PA) activation and plasminogen activator inhib-
itor (PAl-l) inhibition (21-24) . Plasma and serum viscosity
are also reduced by sulodexide (24-30) . Sulodexide has been
widely demonstrated in patients with peripheral atheroscle-
rotic obstructive disease to be clinically efficacious (25,31-
41) .
The aim of this prospective, multicenter, randomized trial
was to determine whether sulodexide was effective in pre-
venting cumulative mortality and cardiovascular mortality
and events in patients after an acute myocardial infarction .
Methods
Eligibility criteria. Patients, irrespective of gender or
age, who had had an AMI were potential candidates for the
study, provided that they did not have severe impairment of
renal (plasma creatinine >2
mg/dl)
or hepatic function,
malignant disease with a life expectancy of <2 years or
required the use of anticoagulant or antiaggregant treatment .
Diagnosis of myocardial infarction was based on the criteria
of the World Health Organization (42) . Patients gave written
informed consent to participate in the study before entry . A
total of 71 hospitals throughout Italy participated in the
study, and the trial was approved by their individual ethics
committees .
Design of the trial. The study was a prospective multi-
center trial . On discharge from the coronary care unit,
eligible patients were allocated to one of two parallel groups
(sulodexide or control), according to a randomization sched-
ule arranged in blocks of 10 for each center . Patients in both
groups were receiving cardiovascular therapy as prescribed
by their specialist . Patients receiving nitrate derivatives,
beta-adrenergic blocking agents, calcium channel blockers,
digitalis, diuretic drugs and antiarrhythmic drugs were in-
cluded in the study . Patients receiving heparin, oral antico-
agulants, antiplatelet or fibrinolytic agents were excluded
from the study, and any patient requiring these medications
during the course of the study was excluded .
Adherence to the study protocol was recorded at each
follow-up visit. Data were collected and analyzed by an
independent contract research organization (Hyperphar srl,
Milan). An independent Ethical Committee and a Safety
Monitoring Board were responsible for decisions regarding
the safe conduct and continuation of the study .
Treatment and patient evaluation . Patients who were
assigned to the test group were treated with sulodexide
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between 7 and 10 days after acute myocardial infarction at a
dose of 600 of lipoprotein-lipase--releasing units (LRU)/day
intramuscularly for 30 days and subsequently at an oral dose
of 1,000 LRU/day in two equally divided doses for 11
months. Follow-up appointments were scheduled at 3, 6, 9
and 12 months after entry . Each visit included a medical
history, physical examination, 12-lead electrocardiogram
(ECG) at rest and a two-dimensional echocardiographic
study. Particular care was taken to obtain images of the
cardiac apex from both long- and short-axis projections,
minimizing near field artifacts . Left ventricular thrombus
was diagnosed when an echogenic mass distinct from the
ventricular wall was seen in association with a wall motion
abnormality from the apical four chambers of the long-axis
and short-axis views of the left ventricle and cardiac apex
(43) .
End points. Cumulative mortality, cardiovascular mor-
tality and cardiovascular events were the primary end points
of the study. Cardiovascular events were defined as reinfarc-
tion (confirmed by ECG and assay of cardiac enzymes), deep
vein thrombosis (confirmed by phlebography), pulmonary
embolism (confirmed by scintigraphy), systemic arterial em-
bolism (confirmed by angiography), cerebral vascular acci-
dents and development of ventricular thrombus at the first
echocardiographic evaluation . After a clinical episode of
transient ischemia or stroke, the diagnosis of cerebral throm-
boembolism was made when a computed tomographic scan
performed within 14 days either showed normal findings or
evidence of cerebral infarction.
Both fatal and nonfatal events were considered ; recurrent
events in the same subject were considered as separate
events. All events were documented and verified by medical
records, autopsy reports or death certificates . Supplemen-
tary evidence was provided by relatives .
Whenever the patient reported an undesirable event that
the attending physician believed could have been related to
treatment, the patient was recorded as having withdrawn
from the study because of treatment intolerance and the
associated treatment was stopped .
Statistical analysis . In calculating the number of patients
required for the study, it was assumed that the 1-year rate of
cardiovascular events would be 10% in the control group and
that it would be reduced to 7% with sulodexide treatment
(3,6) . The type I error (alpha) was set at 5% (two-sided) and
the type It error (beta) at 10%. The chi-square test (corrected
according to Yates where appropriate) and the Student
independent sample t test were used to analyze the differ-
ence between the groups at baseline . Survival was evaluated
by means of log-rank chi-square statistics, regardless of
stratification, and with the Mantel-Haenszel test when strat-
ified according to the use of beta-blockers . Additional sta-
tistics used for preliminary analysis included logit-log multi-
ple regression and the Lee and Desu survival analysis test
(44) .
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Table 1. Characteristics of Patients at Baseline
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Results
Overall, 69 centers took part in the study, contributing
between I I and 121 cases each. Four centers contributed
<20 patients and 10 centers contributed >80 . Patient entry
at each center was well balanced between treatment groups
because of the block design of the randomization table .
Preliminary analysis of the effect of the allocation to a center
in the overall model showed that this factor had no signifi-
cant influence and thus no corrections for the center were
made in subsequent analyses . A total of 2,016 patients were
assigned to receive sulodexide and 1,970 were allocated to
the control group . Apart from age, where a small, clinically
unimportant yet statistically significant difference was de-
tected (59 .3 ± 9.8 years in the sulodexide group vs . 60.1 ±
9.9 years in the control group ; p = 0.05), patient character-
istics were well balanced between the two groups (Table 1) .
Consequently, the age effect and the ageltreatraent interac-
Table 2 . Reast)re fnr Withdrawal From the Study
*p < 0.05. Unless otherwise indicated, values expressed are mean value ± SD . CK = creatinckinase, CK-MB
creatine kinase isoenzymes ; ICU = intensive care unit .
29
tion were considered in all preliminary analyses and are
reported here whenever they affect data interpretation .
Mortality. In the control group, 1,681 patients were still
alive at the end of the study ; 140 had died : 129 of cardiovas-
cular causes and I I of unrelated noncardiovascular causes.
In addition, 17 patients were lost to follow-up and 132
withdrew from the treatment. Of those lost from the control
group, three had reached the "survival to 1 year" end point,
as had four of those who subsequently withdrew .
In the sulodexide group, 1,705 patients were still alive at
the end of the study ; 97 had died, 83 of cardiovascular causes
and 14 of unrelated noncardiovascular causes . In addition .
20 patients were lost to follow-up and 194 withdrew from
treatment (Table 2) . Of those lost from the sulodexide group,
three had reached the "survival to 1 year" end point, as had
I I of those who withdrew . The need for aortocoronary graft
surgery was the same in both groups, as was the propor, ion
Cl = confidence interval
; CV cardiovascular ; NSAIDs
nonsteroid anti-inflammatory drugs .
Variable
Sulodexide Group
(n = 2,016)
Control Grodn
(n = 1,970)
Male/female
1,667/349
1 .6131357
Age (yr)
59 .3 = 9 .8 60.1 ± 19*
Weight (kg)
72 .7 ± 10
72 .9 ± 9 .5
Hypertension
29
28
Diabetes (%)
11 10
Previous myocardial infarction (%)
18
19
Site of myocardial infarction (%)
Anterolateral 27 .0
27 .5
Extensive anterior 5 .3
6 .3
Inferior
W 30.8
Other (specified)
5 .9 6 .7
Undefined 30 .4 28 .7
CK peak (mU/ml) 1,264 .6 ± 1,150 .4 1,269.1
	
1,133 .3
CIUMB peak (mU/ml)
108 .6 ± 163 .3 109.9 207 .3
Therapy in ICU (%)
Standard therapy (excluding fibrinolytic agents and heparin) 59 .1 56 .5
Heparin 22 .1
25
.3
Fibrinolytic agents and heparin 18 .8
18 .2
Days from onset or nvocammi infarction to randomization 7 .2 ± 5 .5 7.6 ± 119
Factor
Control Group (a - 1,970)
Sulodexide Group (n 2,016)
p Value
(log-rank chi-square tests
No .
% 95% CI No.
% 95170 Cl
Total 132
6 .7 5.6-7 .8
194 9 .6 8 .3-10.9
M008
Adverse drug reactions
18 0 .9
0 .5-1 .3
Nonallowed treatments
23 1 .2 0 .7-1 .6
54 2
.7 2.0-3 .4 0
Antiplatelet agents 9 0.5
0 .2-0.8 19
0 .9 0 .5-1 .4
0 .0988
NSAIDs with known
antiplatelet activity
14 0.7 0.3-1 .1 35
1 .7
1 .2-2 .3
0 .0052
Coronary bypass surgery
25 1 .3 0 .8-1 .8 23
1 .1
0 .7-1
.6
0
.7114
Nonmedical causes 68
3.5 2.6-4 .3
80 4 .0
3 .1-4 .8
0 .3898
Non-CV diseases
16 0.8
0 .4-1 .2 19 0 .9
0 .5-1 .4
0 .66G0
30
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Table 3. Death From All Causes in the Entire Study Sample
of nonmedical withdrawals and those due to the onset of
other diseases. A total of 18 patients withdrew from treat-
ment in the sulodexide group after the onset of adverse drug
reactions, and significantly more (2 .7%) patients given sulo-
dexide withdrew because of disallowed treatments in com-
parison with the control group (1.2%, p = 0. 5, log-rank
chi-square).
Data on mortality, including 95% confidence intervals,
are shown in Table 3 . Analysis of the total study group
revealed that death occurred in 140 patients (7.1%) in the
control group and 97 patients (4 .8%) in the sulodexide group,
indicating a statistically significant (32%) reduction in risk
for the sulodexide group compared with the control group
(p = 0.0022, log-rank chi-square test) (Fig . 1) .
To avoid the risk of bias due to the relatively large
proportion of patients withdrawn from the trial, the analysis
of mortality was repeated for those patients who reached one
of the study end points (Table 4) and confirmed the preced-
ing results (p = 0.0011). The observed mortality risk reduc-
Cl = confidence interval ; CV = cardiovascular .
days
100
200
tion in the sulodexide group, regardless of considered sam-
ple, appears to be due to a decreased risk of death from heart
failure (p = 0 .0101), other cardiovascular events (including
three fatal cerebrovascular events, p = 0 .0417) and to some
extent from sudden death (p = 0 .0659) (p = 0 .0464 for the
total study group) .
Multiple regression analysis of the percent of survivors
versus time indicated a significant effect of gender ; mortality
rate 5.1% in men and 9.8% in women (p = 0 .0001 by log-rank
corrected chi-square test) and a significant age effect (the
mortality rate increasing with age) .
Preliminary analysis by logit-log multiple regression indi-
cated that gender and age, although significant by them-
selves in predicting survival, did not influence the treatment
effect to a significant extent . Thus, neither factor was
considered in the overall evaluations .
The treatment effect was also confirmed after stratifying
patients according to whether they were prescribed beta-
blockers during the follow-up period (Mantel- Haenszel test
P
300 400
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Figure 1
. Cumulative proportion of
death from all causes in the study
group according to the assigned
treatment .
Control Group
(n = 1,970)
Sulodexide Group
(n = 2,016) Risk Reduction
Factor
No . %
95% Cl
(%) No .
%
95% Cl
(%)
%
95% CI
(%1
p
Value
Experimental
Power
Death (all reasons) 140 7 .1 6 .0-8
.2 97 4.8 3 .9-5 .7 32
12-53 0.0022 0 .85
Reinfarction
15 0.8 0 .4-1 .1 18 0.9 0.5-1 .3 -17 -91-57 0.6456
Heart failure 30
1 .5 1 .0-2 .1 13 0.6 0.3-1 .0 58 15-100 0,0074 0.75
Sudden death 50 2.5 1,8-3 .2 33
1 .6 1 .1-2 .2
36 1-71 0 .0464 0.47
All other CV accidents
34 1 .7 1 .2-2 .3 19 0 .9 0.5-1 .4 45 4-87 0 .0308 0.55
Non-CV causes 11 0.6
0
.2-0
.9 14 0 .7 0.3-1 .1 -24
-112-63 0 .5865
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Table 4
. Death From All Causes in the Patients Reaching an End Point
Abbreviations as in Table 3 .
= 9 .407, p = 0 .002). The mortality rate for the entire study
group, irrespective of cause, was 6 .2% (227 of 3,649 patients)
for those who had not received beta-blockers and 3% (10 of
337 patients) for those who had received beta-blockers .
According to treatment group, the mortality rate for the
control group was 7.4% (134 of 1,803 patients) and 3 .6% (6 of
167 patients), respectively . In the sulodexide group, the
mortality rate was 5% (93 of 1,846 patients) and 2 .4% (4 of
170 patients), respectively . Even allowing for treatment
effect, there was still a significant effect of beta-blockers on
survival (Mantel-Haenszel test = 5 .860; p = 0.015), suggest-
ing that a combination of sulodexide and beta-blockers may
be beneficial in enhancing long-term survival after the acute
infarction phase .
Cardiovascular events. During the follow-up period, 158
fatal and nonfatal cardiovascular events occurred in 148
patients (7 .5%) in the control group and 112 fatal and
nonfatal cardiovascular events occurred in 104 patients
(5.2%) in the sulodexide group (Table 5) . Analysis of both
the number of patients and events yielded a significant risk
reduction in the sulodexide group (31%, 95% confidence
interval I I% to 51, p = 0 0023 by log-rank chi-square test) .
Among the events observed, a significant protection ap-
peared evident on left ventricular mural thrombosis (53%,
95% confidence interval 6% to 100%, p = 0 .0266) and fatal
and nonfatal reinfarction (28% ; 95% confidence interval 2%
Table 5. Cardiovascular Events (lethal and nonlethal) in the Entire Study Sample
CONDOREL.1-1 ET AL_
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to 559K p = (10351) . No risk reduction was associated with
monitored treatment with respect to events such as deep
vein thrombosis, cerebrovascular accidents, peripheral vas-
cular accidents or lung embolism .
The time course of the occurrence of both mural throm-
bosis and reinfarction indicated that the risk reduction was
detectable from approximately the end of the 3rd month of
treatment. It therefore seems that the pharmacodynamic
action of sulodexide requires a "prompting" period to cause
detectable risk reduction of these cardiovascular events .
Discussion
Background. Antithrombotic therapy has been shown to
reduce the occurrence of cardiovascular events and death
after acute myocardial infarction . Oral anticoagulants and
low dose heparin similarly reduce the risk of death (8),
reinfarction (8,10), the incidence of postinfarction left ven-
tricular mural thrombosis (45,46) and cerebrovascular acci-
dents (47) . However, aspirin is associated with a relatively
high incidence of gastrointestinal events, especially in the
elderly, and long-term anticoagulant therapy carries a signif-
icant risk of bleeding and requires repeated monitoring by
coagulation tests .
An I l -month period of oral administration of sulodexide
after I month of treatment by the intramuscular route is
C1 = confidence interval .
Control Group
(n w 1081
Sulodexide Group
(n = 1,769)
Risk Reduction
Factor No
952 Cl
No .
95c.
Cl
MI)
95%- Cl
I-")
p
Value
Experimental
Power
Death (all reasoas) 134 7 .5 6 .3-8 .7 86 4.9
3 .9-5,9 35
14-56
0 .0010
0 .88
Reinfarction 15
0 .8 0.4-1 .3 18 0.545
-21 -96-54 0.5799
Watt failure 30 1 .7 1 .1-2 .3
13
0
.7 0 .3-1 .1 56
14-99 0.0101 0 .73
Sudden death 50 2 .8 2 .0-16 33 1 .9
1 .2-2 .5 33 -2-69 0 .0695
0 .38
All other CV accidents 34
1 .9 1 .3-2 .5 19 1 .1 0 .6-1 .6
44 2-85 0 .0417
3 .45
Non-CV causes 5 0 .3 0 .0-0 .5
3 0.2 0 .0-0.4 39 -72-151
0 .4883
Control Group
(n = 1,970)
Sulodexide Group
Risk Reduction
2 .016)
Factor No . %
5% Cl
( 17c) No .
%
95% CI
(%)
5C
95% Cl
(%)
p
Value
Experimental
Power
Occurrence (total patients) 148 7 .5 6 .3-47
104 5 .2 4.2-6 .1 31
11-51 0.0022
0 .83
Occurrence (total events)
158 8 6 .8-9.2 112 5
.6
4.6-6 .6
31 11-50 0.0020
0 .84
Reinfarction
90 4 .6 3,6-5 .5 66 3 .3 2.5-4 .1
28 2-55
0.0351 0 .53
Deep vein thrombosis 8 0 .4 0 .1-0.7
3 0 .1 0.0-0 .3 63
-17-144 0.1217
Cerebrovascular accidents 25
1 .3
0 .8-1 .8
20 1 .0 0.6-1 .4
22 -30-74 0.4077
Peripheral vascular accidents
5 0.3 0.0-0 .5 3 0.1
0.0-0.3 41 -68-151
0 .4592
Left ventricular thrombosis
25 1 .3 11 .8-1 .8 12 0 .6
0.3-0 .9 53
6-100 0.0266 0 .56
Pulmonary embolism 5 0 .3 0.0-0 .5
8 0 .4 0 .1-0 .7 -56
-195-83 0
.4284
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effective in maintaining the anti-Xa activity levels and the
antithrombotic effects obtained after initial intramuscular
injections (25) . These previously documented features of
sulodexide provide the rationale for its use in patients after
myocardial infarction, particularly in those who, because of
advan. :ed age or risk of hemorrhagic complications, require
a drug that is easy to use, is well tolerated and can be used
for long-term treatment .
Evidence. The main result of the present study is the
reduction in total mortality rate that was demonstrated for all
patients allocated to receive sulodexide and for those who
reached only one end point . This appears to be due to a
reduction in death secondary to heart failure, death due to
other cardiovascular events and sudden death . Although the
mortality curves for the sulodexide and control groups
diverge from the beginning of the study (Fig . 1), the risk
reduction for reinfarction occurs to a detectable extent from
approximately the beginning of the 4th month of treatment .
Similarly the risk reduction for mural thrombosis is only
evident after 50 days . The most likely explanation for the
beneficial effects of sulodexide is the antithrombotic prop-
erty of the drug, which leads to a reduction in the rate of
ischemic episodes, reinfarction and sudden death . The chro-
nologic dissociation between the prompt initial benefit on
mortality and the delayed benefits on reinfarction and mural
thrombosis could be related to a significantly earlier occur-
rence of heart failure (p = 0.0143) (44) (Fig . 2), sudden death
(p = 0.0544) and other cardiovascular deaths (p = 0 .0540) in
the control group .
Study limits . The design of this trial did not allow any
antithrombotic therapy, even in the control group . When this
study was designed in 1985, no clear benefit from antithrom-
j
Suiodexide
controls
300 400
botic therapy in terms of survival had been shown in any
trial .
No comparison between sulodexide and other antithrom-
botic drugs can be deduced from this study . However, our
results (reductions in mortality, reinfarction rate and left
ventricular thrombus formation) are consistent with the
reported effects of antiplatelet drugs (9) and oral anticoagu-
lant agents (8) .
An acknowledged limitation of this study is the lack of
double-blind design. It was considered unethical to admin-
ister a placebo by the intramuscular route for a relatively
long period of time (l month), causing the patient inconve-
nience and discomfort without any possible benefit . Further-
more, by not introducing a placebo-treated group, changes in
therapeutic procedures were minimized at the study centers .
However, the end points of the study (death, reinfarction
and thromboembolic events) are unlikely to have been
influenced by the absence of blinding .
Tolerability . Only a few minor side effects were observed
with sulodexide treatment and no reported event was fatal,
or life-threatening, required hospitalization or resulted in
permanent disability . The adverse drug experiences were
two cases of hematoma during intramuscular treatment, four
skin reactions, five cases of epigastralgia and seven cases of
nausea or vomiting (side effects were not considered to be a
reason for withdrawal in the control group) .
Conclusions . The present study provides evidence that
sulodexide reduces the rate of cardiovascular death and late
reinfarction in survivors of myocardial infarction . The drug
also reduces the rate of left ventricular thrombus formation
after infarction . The treatment appears to be safe and well
Figure 2. Cumulative proportion
of death from heart failure in the
study group according to the as-
signed treatment .
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tolerated, even in the elderly, and does not require labora-
tory monitoring or hemostasis .
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